Antibody Drug Conjugate
Antibody Drug Conjugate (ADCs) are monoclonal antibodies attached to biologically active drugs by chemical linkers. These cytotoxic killers are a new frontier in immunotherapy offering tissue targeting capabilities for superior immunological response. Explore the 3D structure of an Antibody Drug Conjugate to learn more about how it combats cancer.
Antibody Drug Conjugate (ADCs) are monoclonal antibodies (mAbs) attached to biologically active drugs by chemical linkers with labile bonds. By combining the unique targeting of mAbs with the cancer-killing ability of cytotoxic drugs, ADCs allow sensitive discrimination between healthy and diseased tissue. Antibody Drug Conjugates are part of a specialized subset of highly potent APIs. This technically challenging type of therapy combines innovations from biotechnology and chemistry to form a new class of highly potent biopharmaceutical drugs.
3D Print of Antibody Drug Conjugates visualized as a volumetric surface and colored blue by the protein’s bFactor. Attached to the surface of the antibody are small cytotoxic molecule drugs.Attached to the surface of the antibody are small molecule drugs.